Related Experiment Video
Updated: Apr 25, 2026
Delivery of In Vivo Acute Intermittent Hypoxia in Neonatal Rodents to Prime Subventricular Zone-derived Neural Progenitor Cell Cultures
Published on: November 2, 2015
Diazoxide promotes oligodendrocyte differentiation in neonatal brain in normoxia and chronic sublethal hypoxia
Ying Zhu1, Christopher C Wendler1, Olivia Shi1
1Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL 32610, United States.
Insights
Diazoxide promotes myelination in preterm infant brain injury by enhancing oligodendrocyte differentiation. This study reveals its mechanism, offering potential therapeutic strategies for periventricular white matter injury (PWMI).
Area of Science:
- Neuroscience
- Developmental Biology
- Pharmacology
Background:
- Periventricular white matter injury (PWMI) is a leading cause of brain damage in preterm infants, characterized by impaired myelination due to oligodendrocyte issues.
- Currently, no effective treatments exist for PWMI, highlighting an urgent need for therapeutic interventions.
- Previous research indicated diazoxide's potential to improve myelination and reduce brain injury in a PWMI model.
Purpose of the Study:
- To elucidate the underlying mechanisms by which diazoxide promotes myelination in the context of PWMI.
- To investigate diazoxide's effects on oligodendrocyte differentiation and myelin gene expression.
Main Methods:
- Utilizing a chronic sublethal hypoxia model of PWMI in developing brains.
- Analyzing the impact of diazoxide on oligodendrocyte progenitor cell (OPC) differentiation.
- Quantifying the expression levels of key oligodendrocyte differentiation markers (Nkx2.2, Sox10) and myelin genes (CNP, MBP).
Main Results:
- Diazoxide treatment significantly increased the proportion of differentiated oligodendrocytes in the cerebral white matter.
- The drug elevated the expression of crucial transcriptional factors Nkx2.2 and Sox10, essential for oligodendrocyte maturation.
- Diazoxide also upregulated the expression of myelin-associated genes, including CNP and MBP.
Conclusions:
- Diazoxide effectively promotes oligodendrocyte differentiation, a critical process for myelination in the developing brain.
- These findings provide mechanistic insights into diazoxide's therapeutic potential for PWMI.
- Diazoxide represents a promising candidate for developing treatments to address defective myelination in preterm infants.
Abstract:
Periventricular white matter injury (PWMI) is the most common cause of brain injury in preterm infants. It is believed that loss of late oligodendrocyte progenitor cells (OPCs) and disrupted maturation of oligodendrocytes contributes to defective myelination in PWMI. At present, no clinically approved drugs are available for treating PWMI. Previously, we found that diazoxide promotes myelination and attenuates brain injury in the chronic sublethal hypoxia model of PWMI. In this study, we investigated the mechanisms by which diazoxide promotes myelination. We observed that diazoxide increases the ratio of differentiated oligodendrocytes in the cerebral white matter, promotes the expression of differentiation-associated transcriptional factors Nkx2.2 and Sox10, and increases the expression of myelin genes CNP and MBP. These results show that diazoxide promotes oligodendrocyte differentiation in the developing brain.
